Biolife solutions stock.

BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.Complete BioLife Solutions Inc. stock information by Barron's. View real-time BLFS stock price and news, along with industry-best analysis.10 nov 2023 ... Byrnes covers the Healthcare sector, focusing on stocks such as Durect, Oncternal Therapeutics, and BioLife Solutions. According to TipRanks, ...BOTHELL, Wash., July 7, 2020 / PRNewswire / -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced the closing of its public offering of 5,951,250 shares of common stock at the public offering price ...The stock lies in the middle of a very wide and strong rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 10.89% during the next 3 months and, with a 90% probability hold a price between $0.00000328 and $0.0002 at the end of this 3-month period.

Nov 9, 2022 · BioLife Solutions, Inc. (BLFS) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to break-even earnings per share a year ago ... Under the terms of the agreement, BioLife will pay $15 million in cash and $15 million in newly issued shares of BioLife common stock for 100% of the outstanding shares of SciSafe. ... About BioLife Solutions BioLife Solutions is a leading supplier of a portfolio of class-defining cell and gene therapy bioproduction tools and services.

BioLife Solutions, Inc. is a life sciences company. The Company develops, manufactures, and markets bioproduction tools and services which are designed to de-risk biologic manufacturing, storage, distribution, and transportation in the cell and gene therapy (CGT) industry and broader biopharma markets.–BioLife Solutions, Inc. (Nasdaq: BLFS) (“BioLife” or the “Company”), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapy (CGT) and the broader biopharma markets, today announced financial results for the fourth quarter and year ended December 31, 2022.

BioLife Solutions, Inc. (BLFS) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to break-even earnings per share a year ago.–BioLife Solutions, Inc. (Nasdaq: BLFS) (“BioLife” or the “Company”), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapy (CGT) and the broader biopharma markets, today announced financial results for the fourth quarter and year ended December 31, 2022.First, BioLife Solutions, Inc. stock is trading at 1.95x book value of equity, which may or may not represent a value proposition. However, it should also be noted the breakdown of its book value ...See BioLife Solutions, Inc. (BLFS) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.

Get the latest BioLife Solutions, Inc. (BLFS) stock news and headlines to help you in your trading and investing decisions.

10 nov 2023 ... BioLife Solutions (NASDAQ: NASDAQ:BLFS) reported a decrease in revenue ... stock comp in Q3. In addition, we eliminated discretionary travel ...

20 sept 2022 ... About BioLife Solutions Stock ... Today, BioLife has a market cap of just over $1 billion, with total revenue of $119.2 million in 2021, an ...10 nov 2023 ... BioLife Solutions (NASDAQ: NASDAQ:BLFS) reported a decrease in revenue ... stock comp in Q3. In addition, we eliminated discretionary travel ...Hedge fund activity in BioLife Solutions, Inc. (NASDAQ:BLFS) Heading into the second quarter of 2020, a total of 9 of the hedge funds tracked by Insider Monkey were long this stock, a change of ...Total revenue for the third quarter of 2023 was $33.3 million, a decrease of $7.4 million, or 18%, from $40.7 million for the third quarter of 2022. There was no COVID related revenue in the third ...The current BioLife Solutions [ BLFS] share price is $13.57. The Score for BLFS is 44, which is 12% below its historic median score of 50, and infers higher risk than normal. BLFS is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.

The estimated net worth of Roderick de Greef is at least $463,582.14 as of November 30th, 2022. Mr. de Greef owns 34,314 shares of BioLife Solutions stock worth more than $463,582 as of November 20th. This net worth estimate does not reflect any other investments that Mr. de Greef may own.... Stock, $0.001 par value of BioLife Solutions, Inc. shall be filed on behalf of the undersigned. November 27, 2020. (Date). Casdin Capital, LLC. By: /s/ Eli ...BioLife Solutions, Inc. (NASDAQ:BLFS – Get Free Report) shares fell 4.2% during trading on Monday . The company traded as low as $13.37 and last traded at $13.49. 76,840 shares changed hands ...Stock Price Forecast. According to 5 stock analysts, the average 12-month stock price forecast for BLFS stock stock is $26, which predicts an increase of 99.62%. The lowest target is $23 and the highest is $29. On average, analysts rate BLFS stock stock as a strong buy.BOTHELL, Wash., Dec. 19, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced plans to announce preliminary 2022 revenue and introduce 2023 revenue guidance before market open on ...BOTHELL, Wash., Sept. 1, 2021 / PRNewswire / -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced that it has closed its acquisition of Sexton Biotechnologies ...

Rhumbline Advisers decreased its holdings in BioLife Solutions, Inc. (NASDAQ:BLFS – Free Report) by 8.1% in the second quarter, Holdings Channel.com reports. The institutional investor owned 80,251 shares of the medical equipment provider’s stock after selling 7,097 shares during the period. Rhumbline Advisers’ holdings in BioLife Solutions were worth $1,774,000 as of its most recent […]

Management will provide an overview of the Company's financial results and a general business update. To access the webcast, log onto the Investor Relations ...BOTHELL, Wash., Jan. 10, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy (CGT) and broader biopharma markets, today announced preliminary revenue for the fourth quarter and full year 2021.BOTHELL - BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ('CGT') and broader biopharma markets, today announced the launch of Ultraguard, the first ever non-toxic, non-hazardous and non-flammable -70-degreeC phase change material ('PCM'), …BOTHELL, Wash., Aug. 8, 2019 / PRNewswire / -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio of best in class bioproduction tools for cell and gene therapies, today announced that it has executed a share exchange agreement to effect the acquisition of SAVSU Technologies, a leading developer of advanced ...Chg %. Market Cap. Evogene Ltd. -0.32%. $32.76M. BLFS | Complete BioLife Solutions Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full …Get the latest BioLife Solutions, Inc. (BLFS) stock quote, history, news and other vital information to help you with your stock trading and investing. See the company's performance outlook, earnings date, dividend and yield, fair value, ratings and more.Aug 11, 2023 · Shares of BioLife Solutions (BLFS 7.11%) were down more than 37% for the week, as of 3:15 p.m. ET on Friday, ... The healthcare company's stock closed last week at $19.22, then dropped to a 52 ... Biolife Solutions Inc (NASDAQ:BLFS) has a beta value of 1.60 and has seen 2.24 million shares traded in the last trading session. The company, currently valued at $596.91M, closed the last trade at $13.25 per share which meant it gained $0.88 on the day or 7.11% during that session. The BLFS stock ...The estimated net worth of Roderick de Greef is at least $463,582.14 as of November 30th, 2022. Mr. de Greef owns 34,314 shares of BioLife Solutions stock worth more than $463,582 as of November 20th. This net worth estimate does not reflect any other investments that Mr. de Greef may own.

Stock Symbol NASDAQ:BLFS ; ... Phone Number 425-402-1400; BioLife Solutions is located in Bothell, Washington, on a high-tech campus that has its roots as a dairy farm. They design, manufacture, and market proprietary and generic cGMP biopreservation media products for cells, tissues, and organs. They also perform contract research and offer ...

BioLife Solutions, Inc. announced that it has received $10.374976 million in funding from Casdin Capital, LLC. Oct. 18. CI. Lake Street Adjusts Price Target on BioLife Solutions to $25 From $34, Maintains Buy Rating. Aug. 09. MT. Transcript : BioLife Solutions, Inc., Q2 2023 Earnings Call, Aug 08, 2023. Aug. 08.

On December 15, 2022, BioLife Solutions, Inc. (NASDAQ:BLFS) stock closed at $18.77 per share. One-month return of BioLife Solutions, Inc. (NASDAQ:BLFS) was -11.46%, and its shares lost 48.63% of ...BOTHELL, Wash., Nov. 4, 2021 / PRNewswire / -- BioLife Solutions, Inc. (the "Company") (Nasdaq: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced changes to its executive management team, effective immediately.2.70% of BioLife Solutions stock is owned by insiders. Learn more on BLFS's insider holdings. Which BioLife Solutions insiders have been buying company stock? The following insider purchased BLFS shares in the last 24 months: Casdin Partners Master Fund, L ($12,648,274.13).BioLife Solutions's headquarters are located at 3303 Monte Villa Pkwy Ste 310, Bothell, Washington, 98021, United States What is BioLife Solutions's phone number? BioLife Solutions's phone number is (425) 402-1400 What is BioLife Solutions's stock symbol?Get the latest BioLife Solutions Inc (BLFS) stock quote, charts, news, and other financial information to help you make more informed trading and investment decisions. See the company's financial performance, balance sheet, cash flow, and earnings per share for the fiscal Q2 2023 ended 6/30/23. Aug 8, 2023 · BioLife Solutions, Inc. (BLFS) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $1.71 per share a year ago. Track Biolife Solutions Inc (BLFS) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors BioLife Solutions, Inc. (BLFS) Stock Price, Quote, News & Analysis BLFS BioLife Solutions, Inc. Stock Price & Overview 5.43K followers $10.95 -0.44 ( -3.86%) 4:00 PM 11/10/23 NASDAQ...Mar 13, 2023 · BioLife Solutions, Inc. (BLFS) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the ... The estimated net worth of Andrew G. Hinson is at least $207,858.00 as of June 15th, 2021. Mr. Hinson owns 17,675 shares of BioLife Solutions stock worth more than $207,858 as of November 3rd. This net worth approximation does not reflect any other investments that Mr. Hinson may own. Learn More about Andrew G. Hinson's net worth.

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced ...BOTHELL, Wash., April 15, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced that it has launched a new line of high capacity controlled rate freezers (HCRF), with an …Dec 1, 2023 · msn.com - November 17 at 10:30 PM. BioLife Solutions (BLFS) was Impacted by Inventory Destocking and Elongated Sales Cycles. finance.yahoo.com - November 16 at 10:07 AM. Analysts Just Shaved Their BioLife Solutions, Inc. (NASDAQ:BLFS) Forecasts Dramatically. finance.yahoo.com - November 16 at 10:07 AM. Instagram:https://instagram. options trading applicationvanguard dividend etfsvirxexpense ratio in etf If you’re looking to donate plasma, Biolife Plasma Centers are a fantastic option. They offer convenient locations, a streamlined donation process, and compensation for your time. In this comprehensive guide, we’ll cover everything you need...The BioLife Solutions stock price gained 3.76% on the last trading day (Friday, 24th Nov 2023), rising from $13.57 to $14.08. During the last trading day the stock fluctuated 11.10% from a day low at $12.79 to a day high of $14.21. The price has risen in 6 of the last 10 days and is up by 23.62% over the past 2 weeks. etrade core portfoliobest conventional loan lenders Broadridge Corporate Issuer Solutions, Inc. P.O. Box 1342 Brentwood, New York 11717 USA (877) 830 - 4936 [email protected] three major U.S. stock exchanges are the New York Stock Exchange (NYSE), the NASDAQ and the American Stock Exchange (AMEX). As of 2014, the NYSE is the largest and most prestigious of the three. The NASDAQ is a virtual stock exchange. uber blade Broadridge Corporate Issuer Solutions, Inc. P.O. Box 1342 Brentwood, New York 11717 USA (877) 830 - 4936 [email protected] Mar 13, 2023 · BioLife Solutions, Inc. (BLFS) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the ...